Zymeworks Long Term Debt 2016-2022 | ZYME

Zymeworks long term debt from 2016 to 2022. Long term debt can be defined as the sum of all long term debt fields.
Zymeworks Annual Long Term Debt
(Millions of US $)
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $4
2015 $
Zymeworks Quarterly Long Term Debt
(Millions of US $)
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31 $5
2016-12-31 $4
2016-09-30
2016-06-30
2016-03-31
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.570B $0.412B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $136.891B 8.36
GSK (GSK) United Kingdom $70.351B 9.82
Bio-Rad Laboratories (BIO.B) United States $10.988B 29.38
QIAGEN (QGEN) Netherlands $10.229B 21.60
Ginkgo Bioworks Holdings (DNA) United States $3.712B 0.00
Biohaven (BHVN) United States $1.540B 0.00
Arcus Biosciences (RCUS) United States $1.505B 0.00
Emergent Biosolutions (EBS) United States $0.429B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.196B 0.00
Enzo Biochem (ENZ) United States $0.109B 0.00
SQZ Biotechnologies (SQZ) United States $0.016B 0.00